Triveni Bio is at the forefront of developing genetically informed precision medicine, particularly targeting immunological and inflammatory (I&I) disorders. Their innovative approach combines insights from human genetics and pathway biology to identify and validate therapeutic targets, enabling the design of functional antibodies that not only bind to these targets but also modulate protein function. This methodology is exemplified in their lead program, TRIV-509, which is a monoclonal antibody designed to inhibit kallikreins 5 and 7 (KLK5/7), proteins critical for maintaining skin barrier integrity. By leveraging genomic data and extensive screening processes, Triveni aims to address conditions like atopic dermatitis, which is characterized by chronic inflammation and barrier dysfunction.

The company’s data platform plays a crucial role in defining patient subpopulations based on genetic variations and treatment responses, allowing for a more tailored therapeutic approach. Triveni's research highlights the significance of KLK5/7 in the pathogenesis of atopic dermatitis, where their overexpression contributes to inflammation and skin barrier issues. By focusing on this mechanism, Triveni is not only advancing their pipeline of therapies but also exploring combination strategies, such as pairing TRIV-509 with IL-13 inhibition, to enhance treatment efficacy. This comprehensive strategy positions Triveni Bio as a leader in the development of next-generation therapies for challenging I&I disorders.

United States

Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. 

Triveni Bio

Company Details